0.01
0.00%
Close of 9 Nov 2026, in AUD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Anatara Lifesciences
Its shares trade on ASX under the ticker ANR.AX. It has been listed since 16 October 2014. In the fiscal year to 30 June 2025, it reported revenue of A$969,456 and a net loss of A$2.0m. At that date it held total assets of A$1.1m and shareholders' equity of A$535,968.
Anatara Lifesciences Ltd. engages in the development of non-antibiotic oral solutions for gastrointestinal diseases in animals and humans. The company is headquartered in Melbourne, Victoria. The company went IPO on 2014-10-16. The firm is engaged in developing and commercializing evidence-based products for gastrointestinal health. The company develops products for human and animal health. Its products include Gastrointestinal ReProgramming (GaRP), Detach, BONIFF, and ANR-pf. Its GaRP Product is a microbiome-targeted multi-component complementary medicine, which is designed to address the primary underlying factors associated with chronic gastrointestinal conditions, such as irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD). Detach is a non-antibiotic approach to aid in the control of diarrheal disease known as scour, which is developed using bromelain. BONIFF is a revised formulation which is applied to dry feed for piglets after weaning, reducing labor input, and simplifying the entire process. ANR-pf is an enriched formulation for poultry in water, designed to allow the full delivery of key additives in a quick and flexible dosing method.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 16 Oct 2014
- Website
- anataralifesciences.com ↗
Leadership
Pay as last reported
- Dr. David BrookesExecutive Chairman of the Board, since 2019A$150,096
- Mr. John MichailidisChief Operating Officer, Executive Director, since 2022
- Mr. Jonathan LindhCompany Secretary, since 2024
- Mr. Dirk van DisselNon-Executive Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Develops non-antibiotic oral solutions for gastrointestinal diseases in animals and humans
- Offers microbiome-targeted products like GaRP for chronic GI conditions
- Has multiple products including GaRP, Detach, BONIFF, and ANR-pf
Weaknesses
- No specific weaknesses mentioned in the provided information
- No financial data or performance metrics provided
- No details on market share or competitive positioning
Opportunities
- Expanding into gastrointestinal health solutions for both human and animal markets
- Potential for growth in non-antibiotic treatments due to rising antibiotic resistance concerns
- Commercialization of evidence-based products for gastrointestinal health
Threats
- Rising antibiotic resistance may increase competition from antibiotic-based treatments
- Dependence on developing and commercializing new products without financial data
- No information on regulatory challenges or market saturation
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.